Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Terry D Hinds

Showing results (21-30 of 101) with videos related to

Pageof 11
Sort By:
Molecules (Basel, Switzerland)|June 2, 2021
Identification of Binding Regions of Bilirubin in the Ligand-Binding Pocket of the Peroxisome Proliferator-Activated Receptor-A (PPARalpha)Darren M Gordon, Stephen H Hong, Zachary A Kipp, et al.
Metabolism: Clinical and Experimental|June 4, 2023
Hepatic insulin receptor: new views on the mechanisms of liver diseaseWang-Hsin Lee, Sonia M Najjar, C Ronald Kahn, et al.
Biomolecules|May 27, 2026
Transforming Toxicity into Therapy: Exploring Bilirubin's Benefits and Its Molecular Role in Cardiac Health and DiseaseMichael I Adenawoola, Zachary A Kipp, Terry D Hinds, et al.
Trends in Endocrinology and Metabolism: TEM|March 2, 2015
Biliverdin reductase isozymes in metabolismLuke O'Brien, Peter A Hosick, Kezia John, et al.
Transplantation Reviews (Orlando, Fla.)|July 10, 2018
Bilirubin, a new therapeutic for kidney transplant?Vikram L Sundararaghavan, Sivjot Binepal, David E Stec, et al.
PPAR Research|May 19, 2016
Timcodar (VX-853) Is a Non-FKBP12 Binding Macrolide Derivative That Inhibits PPARγ and Suppresses AdipogenesisTerry D Hinds, Kezia John, Lucien McBeth, et al.
Biomedicines|February 26, 2025
Urobilin Derived from Bilirubin Bioconversion Binds Albumin and May Interfere with Bilirubin Interacting with Albumin: Implications for Disease PathologyKevin I Williams, Priyanka Suryadevara, Chang-Guo Zhan, et al.
Metabolism: Clinical and Experimental|November 23, 2024
Bilirubin bioconversion to urobilin in the gut-liver-kidney axis: A biomarker for insulin resistance in the Cardiovascular-Kidney-Metabolic (CKM) SyndromeZachary A Kipp, Olufunto O Badmus, David E Stec, et al.
Frontiers in Sports and Active Living|January 30, 2023
Cutting edge concepts: Does bilirubin enhance exercise performance?Kyle D Flack, Libor Vítek, Christopher S Fry, et al.
Oncotarget|April 2, 2016
Glucocorticoid receptor beta increases migration of human bladder cancer cellsLucien McBeth, Assumpta C Nwaneri, Maria Grabnar, et al.
Pageof 11

Showing results (21-30 of 101) with videos related to

Sort By:
Pageof 11
Molecules (Basel, Switzerland)|June 2, 2021
Identification of Binding Regions of Bilirubin in the Ligand-Binding Pocket of the Peroxisome Proliferator-Activated Receptor-A (PPARalpha)Darren M Gordon, Stephen H Hong, Zachary A Kipp, et al.
Metabolism: Clinical and Experimental|June 4, 2023
Hepatic insulin receptor: new views on the mechanisms of liver diseaseWang-Hsin Lee, Sonia M Najjar, C Ronald Kahn, et al.
Biomolecules|May 27, 2026
Transforming Toxicity into Therapy: Exploring Bilirubin's Benefits and Its Molecular Role in Cardiac Health and DiseaseMichael I Adenawoola, Zachary A Kipp, Terry D Hinds, et al.
Trends in Endocrinology and Metabolism: TEM|March 2, 2015
Biliverdin reductase isozymes in metabolismLuke O'Brien, Peter A Hosick, Kezia John, et al.
Transplantation Reviews (Orlando, Fla.)|July 10, 2018
Bilirubin, a new therapeutic for kidney transplant?Vikram L Sundararaghavan, Sivjot Binepal, David E Stec, et al.
PPAR Research|May 19, 2016
Timcodar (VX-853) Is a Non-FKBP12 Binding Macrolide Derivative That Inhibits PPARγ and Suppresses AdipogenesisTerry D Hinds, Kezia John, Lucien McBeth, et al.
Biomedicines|February 26, 2025
Urobilin Derived from Bilirubin Bioconversion Binds Albumin and May Interfere with Bilirubin Interacting with Albumin: Implications for Disease PathologyKevin I Williams, Priyanka Suryadevara, Chang-Guo Zhan, et al.
Metabolism: Clinical and Experimental|November 23, 2024
Bilirubin bioconversion to urobilin in the gut-liver-kidney axis: A biomarker for insulin resistance in the Cardiovascular-Kidney-Metabolic (CKM) SyndromeZachary A Kipp, Olufunto O Badmus, David E Stec, et al.
Frontiers in Sports and Active Living|January 30, 2023
Cutting edge concepts: Does bilirubin enhance exercise performance?Kyle D Flack, Libor Vítek, Christopher S Fry, et al.
Oncotarget|April 2, 2016
Glucocorticoid receptor beta increases migration of human bladder cancer cellsLucien McBeth, Assumpta C Nwaneri, Maria Grabnar, et al.
Pageof 11